This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stryker Corporation - Shareholder/Analyst Call

In totality, there's over 100 years of Stryker experience. If you add up the broader med tech experience of the group, it's closer to 150 years. Reason I'd point that out, it is a seasoned med tech team, and I think that's very important in today's environment, that you understand the management and leadership style that this group brings to the table each and every day.

Our agenda today, you might get a little sick of me because you're going to see me 3 different times, I'm going to cover the overview and I'll drive right into the Neurovascular business because that business reports to me. Kevin will get up, and when Kevin get up here, he'll give a further introduction on his background and talk about our Orthopaedics business. Tim will speak on MedSurg and Spine. For those of you who've participated in the past years, you've heard Tim before and you know the credibility he brings to those businesses. This year, in a new format, we've asked Ramesh to speak on behalf of our International business. He's got one year under his belt evaluating and moving this business. We thought we'd take the opportunity to have him share some of his thoughts both where we are today and what we see in the future. Lonny Carpenter will then speak about our global quality and ops, progress and where we see ourselves going. Again, Lonny is past presenter at this session. I'll then wrap up with a financial overview. And in the interest of I'm sure everybody in the room, we have plenty of time for investor and analyst Q&A. In addition, for those who are here in Mahwah, we do have plant 2 rescheduled, and those we'll meet at the end of the session at the bottom of the stairs.

2 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs